OBN Co-Founds and Subscribes to EDCA
News Feb 05, 2013
OBN has announced its co-founding and support of the European Diagnostic Clusters Alliance (EDCA). This significant step has been taken in support of OBN’s Diagnostic Member Companies.
OBN believes that the first European world class diagnostic cluster has now become a reality through the creation of the EDCA an international non-for-profit organization, headquartered in Brussels.
Through this Alliance, OBN will help to foster and develop collaborative networking between the other allied European diagnostic clusters in order to consolidate the competitiveness of their SMEs.
Access to non-EU markets (USA and Asia) for European medical diagnostic SMEs is also a key objective to the EDCA members.
OBN has been increasing its activity in support of SME diagnostics businesses in the UK in recent years, with last October’s very popular BioTuesday event “Meet with AstraZeneca's Head of Personalized Healthcare & Biomarkers and Biomarker company showcase.”
What does this mean for OBN diagnostics Members? They will gain access to sources of information on potential collaborators, join in grant applications for European funding and have the opportunity to network with European colleagues and potential partners.
EDCA members participated in OBN’s BioTrinity 2012, Europe’s premier biopartnering and investment conference and it is hoped that OBN will lead a party of OBN Diagnostics company members to the forthcoming Euromediag International Convention in Montpelier in July.
OBN’s involvement includes Advisory Board Member Bruce Savage as treasurer and lead contact.
Dr Jon Rees, CEO of OBN, said: “I am delighted that OBN is a member of the EDCA, this demonstrates our ongoing engagement with Medical Technology companies, membership of the EDCA will strengthen our offering to member companies and will give them opportunities to collaborate and partner with organizations throughout Europe and beyond. Redoubling our commitment to this sector, OBN is now planning towards a new medtech and diagnostics investing and partnering conference.”
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE